⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK